Skip to main content
Clinical Trials/NCT03680677
NCT03680677
Recruiting
Not Applicable

Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Abramson Cancer Center at Penn Medicine1 site in 1 country20 target enrollmentSeptember 21, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Leukemia, Acute
Sponsor
Abramson Cancer Center at Penn Medicine
Enrollment
20
Locations
1
Primary Endpoint
Non-Relapse Mortality (NRM) in Frail, Pre-Frail, and Non-Frail patients
Status
Recruiting
Last Updated
9 months ago

Overview

Brief Summary

The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.

Registry
clinicaltrials.gov
Start Date
September 21, 2018
End Date
November 1, 2026
Last Updated
9 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Non-Relapse Mortality (NRM) in Frail, Pre-Frail, and Non-Frail patients

Time Frame: 1-month

NRM will be defined as death without evidence of disease progression or relapse.

Secondary Outcomes

  • NRM by Intensity of Treatment(1-month and 6-month)

Study Sites (1)

Loading locations...

Similar Trials